UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Leukemia, 2021-01, Vol.35 (1), p.1-17

2021

Volltextzugriff (PDF)

Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies

American journal of hematology, 2023-05, Vol.98 (5), p.794-800

2023

Volltextzugriff (PDF)

Thromboembolic events in polycythemia vera

Annals of hematology, 2019-05, Vol.98 (5), p.1071-1082

2019

Volltextzugriff (PDF)

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

American journal of hematology, 2020-06, Vol.95 (6), p.594-603

2020

Volltextzugriff (PDF)

Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives

Cancer, 2024-06, Vol.130 (12), p.2091-2097

2024

Volltextzugriff (PDF)

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

The New England journal of medicine, 2012-03, Vol.366 (9), p.787-798

2012

Volltextzugriff (PDF)

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

The New England journal of medicine, 2021-03, Vol.384 (11), p.1028-1037

2021

Volltextzugriff (PDF)

Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature

British journal of haematology, 2024-07, Vol.205 (1), p.48-60

2024

Volltextzugriff (PDF)

From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?

Leukemia, 2020-11, Vol.34 (11), p.2837-2839

2020

Volltextzugriff (PDF)

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts

British journal of haematology, 2022-07, Vol.198 (2), p.317-327

2022

Volltextzugriff (PDF)

Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies

Cancer, 2023-06, Vol.129 (11), p.1681-1690

2023

Volltextzugriff (PDF)

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Leukemia, 2022-05, Vol.36 (5), p.1408-1411

2022

Volltextzugriff (PDF)

Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia

The New England journal of medicine, 2014-07, Vol.371 (2), p.188-189

2014

Volltextzugriff (PDF)

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Haematologica (Roma), 2015-09, Vol.100 (9), p.1139-1145

2015

Volltextzugriff (PDF)

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Journal of hematology and oncology, 2017-09, Vol.10 (1), p.156-6, Article 156

2017

Volltextzugriff (PDF)

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

Journal of clinical oncology, 2011-10, Vol.29 (29), p.3907-3913

2011

Volltextzugriff (PDF)

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2881-2892

2021

Volltextzugriff (PDF)

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Journal of clinical oncology, 2011-02, Vol.29 (6), p.761-770

2011

Volltextzugriff (PDF)

Clonal evolution in hereditary thrombocytosis with MPL T487A mutation

Pediatric blood & cancer, 2023-02, Vol.70 (2), p.e29905-n/a

2023

Volltextzugriff (PDF)

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients

Haematologica (Roma), 2021-03, Vol.106 (3), p.863-864

2021

Volltextzugriff (PDF)

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

Haematologica (Roma), 2019-08, Vol.104 (8), p.1580-1588

2019

Volltextzugriff (PDF)

Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement

British journal of haematology, 2022-02, Vol.196 (3), p.676-680

2022

Volltextzugriff (PDF)

Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC‐PM

American journal of hematology, 2024-04, Vol.99 (4), p.741-744

2024

Volltextzugriff (PDF)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

Haematologica (Roma), 2022-07, Vol.107 (7), p.1599-1607

2022

Volltextzugriff (PDF)

1 – 25 von 364

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBlood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(345)
Mit Volltextzugriff
(314)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(187)
Life Sciences & Biomedicine
(186)
Hematology
(147)
Humans
(147)
Oncology
(76)
Myelofibrosis
(69)
Female
(66)
Male
(65)
Middle Aged
(57)
Mutation
(43)
Aged
(42)
Adult
(41)
Polycythemia Vera
(38)
Treatment Outcome
(34)
Primary Myelofibrosis - Drug Therapy
(33)
Anemia
(31)
Life Sciences
(31)
Patients
(29)
Tumors
(29)
Janus Kinase 2 - Genetics
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Clinical Lymphoma, Myeloma And Leukemia
(51)
Journal Of Clinical Oncology
(43)
Haematologica
(29)
Hemasphere
(21)
British Journal Of Haematology
(20)
Leukemia
(19)
The Lancet. Haematology
(11)
The New England Journal Of Medicine
(11)
American Journal Of Hematology
(10)
Blood Advances
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(10)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies

Thromboembolic events in polycythemia vera

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature

From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts

Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Clonal evolution in hereditary thrombocytosis with MPL T487A mutation

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement

Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC‐PM

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

Aktive Filter

Suchergebnisse filtern